Do Allergy Drops Work? The SLIT Evidence and What to Expect

Allergy drops are supported by moderate-grade evidence, not absolute proof. The JAMA 2013 review by Lin and colleagues pooled 63 randomized controlled trials and graded the evidence as moderate that sublingual immunotherapy reduces allergic rhinitis and conjunctivitis symptoms; 9 of 36 symptom studies showed greater than 40% improvement. A Cochrane review of 60 trials found a significant reduction in symptoms and rescue medication versus placebo. Moderate grade means the findings are consistent and clinically meaningful but carry more uncertainty than the strongest pharmaceutical data. In plain terms: drops help many people, the benefit is real, but individual results vary and cannot be guaranteed.

FDA-approved SLIT products are tablets, not liquid drops: Grastek for timothy grass, Oralair for a five-grass mix, Ragwitek for ragweed, and Odactra for house dust mites. These tablets went through full clinical trials for a single allergen each. Custom liquid allergy drops, by contrast, are compounded from allergen extracts and used off-label in the United States; they are not FDA-approved as a route of administration. Drops allow personalized multi-allergen mixes that tablets cannot, which appeals to people allergic to several things. The trade-off is that the regulatory and standardization bar for drops is lower than for the approved tablets, so honest hedging about evidence quality matters.

Most people do not feel immediate relief. The immune system needs months to begin shifting toward tolerance, so many patients notice early symptom easing within the first few months or during their first treated allergy season. The deeper, disease-modifying benefit that can last after stopping generally requires at least three years of consistent daily use, with many courses running three to five years. Skipping doses slows progress, so consistency matters more than speed. If you have taken drops daily for several months and notice no change at all, that is worth discussing with your provider to confirm the right allergens and dose are being targeted.

Neither is simply better; they involve different trade-offs. Both shots (subcutaneous immunotherapy) and drops (sublingual immunotherapy) aim to build tolerance to the same allergens. Allergy drops carry a lower risk of systemic reactions than shots and can be taken at home without needles, which many people prefer. Shots have a longer and more standardized evidence record for certain allergens. The right choice depends on your specific allergens, your tolerance for needles and clinic visits, and a conversation with a licensed allergist. Comparative claims should always be hedged, because head-to-head evidence is limited and the best option is individual rather than universal.

Allergy drops are not a cure. They are disease-modifying, meaning they can address the underlying allergic response rather than only masking symptoms the way antihistamines do, and they may provide long-term relief that persists after a completed multi-year course. But no immunotherapy guarantees you will be allergy-free, and results vary from person to person. A more accurate expectation is meaningful symptom reduction and less reliance on rescue medications for many patients, rather than total elimination of allergies. Setting that expectation up front helps people stay consistent with the daily routine, which is what gives drops their best chance of working over the long term.